To this end, we tested the new long-acting GLP-1 agonist dulaglutide and the SGLT-2 inhibitor empagliflozin alone or in combination in a mouse model of NASH. This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.